Form 4: Revance Therapeutics CFO Tobin Schilke Reports Stock Award Vesting
SEC Form 4 Filing
Revance Therapeutics CFO Tobin Schilke reports the vesting of performance-based restricted stock units (PSUs) based on the achievement of revenue goals.
Summary
- On February 3, 2025, Tobin Schilke, CFO of Revance Therapeutics, reported a transaction related to the vesting of performance-based restricted stock units (PSUs).
- The vesting pertains to PSUs granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.
- The Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on the achievement of a revenue goal, measured from January 1, 2024, through December 31, 2024.
- The vesting was also subject to the Reporting Person remaining in continuous service through the vesting date.
- Schilke acquired 6,888 shares of common stock as a result of the PSU vesting at a price of $0.
- Following the transaction, Schilke beneficially owns 201,554 shares of Revance Therapeutics common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests the company met certain revenue goals, which is a positive indicator. However, it's a routine filing and doesn't necessarily indicate significant outperformance.
Positives
- The vesting of PSUs indicates that Revance Therapeutics achieved certain revenue goals, as certified by the Compensation Committee.
- Tobin Schilke's continued service through the vesting date is a positive sign of stability in the company's leadership.
Industry Context
This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency into the alignment of management incentives with company performance.
Stakeholder Impact
- Shareholders may view the PSU vesting as a positive sign, indicating that management is incentivized to achieve revenue goals.
- Employees may be motivated by the company's achievement of revenue targets.
Key Dates
| Date | Description |
|---|---|
| January 31, 2023 | Date the performance-based restricted stock units (PSUs) were granted. |
| January 1, 2024 December 31, 2024 | Period for measuring revenue goal achievement for PSU vesting. |
| February 3, 2025 | Date of the PSU vesting transaction. |
| February 5, 2025 | Date of the signature on the Form 4 filing. |
Keywords
Revance Therapeutics, Tobin Schilke, CFO, PSU, Vesting, Form 4, Revenue Goals, Compensation Committee, Beneficial Ownership, RVNC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.